Feasibility study of FOLFIRINOX as first-line chemotherapy for metastatic pancreatic cancer (KOBE FOLFIRINOX study)

被引：0
|
作者：
Hatachi, Yukimasa [1 ]
Satake, Hironaga [1 ]
Kotake, Takeshi [1 ]
Ogata, Takatsugu [1 ]
Okita, Yoshihiro [2 ]
Yasui, Hisateru [1 ]
Tsuji, Akihito [2 ]
机构：
[1] Kobe City Med Ctr Gen Hosp, Dept Med Oncol, Kobe, Hyogo, Japan
[2] Kagawa Univ Hosp, Dept Clin Oncol, Miki, Kagawa, Japan
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-104
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Effect of PRMT1 and ZEB1 expression on first-line FOLFIRINOX chemotherapy response in patients with locally advanced or metastatic pancreatic cancer
    Coskun Gencalp, C.
    Sutcuoglu, O.
    Ogut, B.
    Ozdemir, N.
    ANNALS OF ONCOLOGY, 2024, 35 : S155 - S155
  • [42] A phase II study of modified FOLFIRINOX for chemotherapy-na⟨ve patients with metastatic pancreatic cancer
    Ozaka, Masato
    Ishii, Hiroshi
    Sato, Tosiya
    Ueno, Makoto
    Ikeda, Masafumi
    Uesugi, Kazuhiro
    Sata, Naohiro
    Miyashita, Kouichirou
    Mizuno, Nobumasa
    Tsuji, Kunihiro
    Okusaka, Takuji
    Furuse, Junji
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (06) : 1017 - 1023
  • [43] Prognostic and predictive significance of inflammatory markers in patients with locally advanced unresectable and metastatic pancreatic cancer treated with first-line chemotherapy FOLFIRINOX or Gemcitabine/Nabpaclitaxel
    Novisedlakova, Maria
    Chovanec, Michal
    Ciernikova, Sona
    Danihel Jr, Ludovit
    BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY, 2024, 125 (11): : 745 - 758
  • [44] Defining Eligibility of FOLFIRINOX for First-Line Metastatic Pancreatic Adenocarcinoma (MPC) in the Province of British Columbia A Population-based Retrospective Study
    Ho, Maria Yi
    Kennecke, Hagen F.
    Renouf, Daniel J.
    Cheung, Winson Y.
    Lim, Howard J.
    Gill, Sharlene
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2017, 40 (06): : 552 - 554
  • [45] Modified FOLFIRINOX versus gemcitabine plus oxaliplatin as first-line chemotherapy for patients with locally advanced or metastatic cholangiocarcinoma: a retrospective comparative study
    Zou, Lu
    Li, Xuechuan
    Wu, Xiangsong
    Cui, Jiujie
    Cui, Xuya
    Song, Xiaoling
    Ren, Tai
    Han, Xusheng
    Zhu, Yidi
    Li, Huaifeng
    Wu, Wenguang
    Wang, Xu'an
    Gong, Wei
    Wang, Liwei
    Li, Maolan
    Lau, Wan Yee
    Liu, Yingbin
    BMC CANCER, 2021, 21 (01)
  • [46] FOLFIRINOX in locally advanced or metastatic pancreatic cancer
    Faris, Jason Edward
    Hong, Theodore S.
    McDermott, Shaunagh
    Guimaraes, Alexander R.
    Sahani, Dushyant
    Clark, Jeffrey W.
    Ryan, David P.
    Blaszkowsky, Lawrence Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [47] Second-line treatment after disease progression following first-line chemotherapy with modified FOLFIRINOX in advanced pancreatic cancer patients
    Vivaldi, C.
    Vasile, E.
    Fornaro, L.
    Caparello, C.
    Musettini, G.
    Pasquini, G.
    Lencioni, M.
    Ricci, S.
    Falcone, A.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S456 - S457
  • [48] FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
    Vaccaro, Vanja
    Sperduti, Isabella
    Milella, Michele
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (08): : 768 - 769
  • [49] Modified-FOLFIRINOX in metastatic pancreatic cancer: A prospective study in Chinese population
    Li, Xiang
    Ma, Tao
    Zhang, Qi
    Chen, Yi-Gang
    Guo, Cheng-Xiang
    Shen, Yi-Nan
    Sun, Pei-Wei
    Li, Guo-Gang
    Gao, Shun-Liang
    Que, Ri-Sheng
    Lou, Jian-Ying
    Yu, Ri-Sheng
    Yuan, Ying
    Wei, Qi-Chun
    Wei, Shu-Mei
    Zhang, Yun
    Zheng, Lei
    Bai, Xue-Li
    Liang, Ting-Bo
    CANCER LETTERS, 2017, 406 : 22 - 26
  • [50] Primary Granulocyte Colony-Stimulating Factor Prophylaxis in Metastatic Pancreatic Cancer Patients Treated with FOLFIRINOX as the First-Line Treatment
    Jung, Jae Hyup
    Shin, Dong Woo
    Kim, Jaihwan
    Lee, Jong-Chan
    Hwang, Jin-Hyeok
    CANCERS, 2020, 12 (11) : 1 - 9
12345